Research Article

m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer

Figure 5

The expression of immune checkpoints in bladder cancer. (a) The mRNA level of PD-L1, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, TIGIT, and SIGLEC15 in cluster 1 and cluster 2 of bladder cancer. (b) The mRNA level of CTLA4, TIGIT, and SIGLEC15 is upregulated in bladder cancer compared with normal tissues. and .
(a)
(b)